ERBB2 and metastatic neoplasm: While a general conversion of subtypes was seen in 36% of patients who progressed from primary to metastatic disease in the AURORA study [48], the change from HER2-E into luminal subtypes was rarely observed, suggesting that the HER2-E subtype may be more stable.